PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:		(11) International Publication Number: WO 97/40017
C07D 231/00, 257/00, 271/00, 285/00	A3	(43) International Publication Date: 30 October 1997 (30.10.97)
(21) International Application Number: PCT/DK9 (22) International Filing Date: 17 April 1997 (1 (30) Priority Data: 0464/96 19 April 1996 (19.04.96) (71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo A 2880 Bagsvaerd (DK).	17.04.9 D	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, I.T, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF,
(72) Inventors: ANDERSEN, Henrik, Sune; Kastelsvej 2 DK-2100 København Ø (DK). MØLLER, Niels Hundahl; Midtermolen 4,3, DK-2100 København i MADSEN, Peter; Ulvebjerg 7, DK-2880 Bagsvaerd	s, Pete Ø (DK	With international search report. Before the expiration of the time limit for amending the
		÷

(54) Title: MODULATORS OF MOLECULES WITH PHOSPHOTYROSINE RECOGNITION UNITS

(57) Abstract

The present invention relates to novel organic compounds, to methods for their preparation, to compositions containing them, to their use for treatment of human and animal disorders, to their use for purification of proteins or glycoproteins, and to their use in diagnosis. The invention relates to modulation of the activity of molecules with phospho-tyrosine recognition units, including protein tyrosine phosphatases (PTPases) and proteins with Src-homology-2 domains, in *in vitro* systems, micro-organisms, eukaryotic cells, whole animals and human beings. The novel organic compounds are compounds of the general formula (I) (L)_n--Ar₁-R₁-A, wherein (L)_n, n, Ar₁, R₁ and A are defined as defined in the application.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain ·	LS	Lesotho	SI	Slovenia
AM	Amenia	Pl	Finland	1.T	Lithuania	SK	Slovakia
-AT	Austria	PR	France .	LU	Luxembourg	SN	Senegal
	Australia	GA	Gabon .	LV	Latvia	SZ	Swaziland
AU AZ	Austrana Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
	Bosnia and Herzegovina	CR CD	Georgia	MD	Republic of Moldova	TG	Togo
BA		GH	Ghana	MG	Madagascar	T)	Tajikistan
B8	Barbados	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BE	Belgium	GR	Greece		Republic of Macedonia	TR	Turkey
BF	Burkina Faso	HU		ML	Mali	TT	Trinidad and Tobago
BG	Bulgaria	IE.	Hungary Ireland	MN	Mongolia	UA	Ukraine
BJ	Benin		larael	MR	Mauritania	UG	Uganda
BR	Brazil	IL To	***	MW	Malawi	US	United States of America
BY	Belarus	IS	Iceland	MX	Mexico	UZ	Uzbekistan
CA	Canada	IT	kaly	NE NE		VN	Viet Nam
CF	Central African Republic	JP	Japan		Niger	YU	Yugoslavia
CG	Congo	KE	Kenya	NL	Netherlands	zw	Zimbabwe
CH	Switzerland	KG	Kyrgyzsian	NO	Norway	ZW	Zimotowe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Kores	PŤ	Portugal		•
CU	Cuba	ΚZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		•
DE	Germany	u	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		•
EE	Estonia	LR	Liberia	SG	Singapore		

Inter .onal application No.
PCT/DK 97/00166

			101/01/01/01		
A. CLASSIFICAT	TION OF SUBJECT MATTER				
IPC6: C07D 2 According to Internal	31/00, CO7D 257/00, CO7D 271 tional Patent Classification (IPC) or to both na	/00, CO7D 285,	/00 IPC		
B. FIELDS SEAR					
Minimum documents	tion searched (classification system followed by	classification symbols)		·	
IPC6: CO7D				ah a Galda assanbad	
	hed other than minimum documentation to the classes as above	extent that such docur	nents are included in	the nerds searched	
Electronic data base o	consulted during the international search (name	of data base and, when	e practicable, search	terms used)	
CAPLUS, WPI					
C. DOCUMENTS	CONSIDERED TO BE RELEVANT		·		
Category* Citation	n of document, with indication, where app	propriate, of the rele	vant passages	Relevant to claim No.	
	AHEDRON, Volume 52, No 30, I "Synthesis of a Diflurophosp Phosphatase Inhibitor Design Structure of a PTP1B-Bound L page 9963 - page 9970	phonomethyl-Co ned from the X	ntaining	1-6,8,13-15, 18-22	
A				7,9-12,16, 23-32	
	AHEDRON LETTERS, Volume 33, Mark S. Smyth et al, "A Gene Preparation of Benzylic x,x- Acids; Non-Hydrolyzable Mime Phosphotyrosine" page 4137	eral Method fo Difluorophosp etics of	r the honic	1-6,8,13-15, 18-22	
A		,	·	7,9-12,16, 23-32	
X Further docum	nents are listed in the continuation of Box	C. X See p	atent family anne	x.	
"A" document defining	of cited documents: the general state of the art which is not considered	date and not in	published after the int conflict with the appli r theory underlying the	ernational filing date or priority ication but cited to understand invention	
"L" document which a	at published on or after the international fiting date may throw doubts on priority claim(s) or which is	considered nov		claimed invention cannot be cred to involve an inventive se	
special reason (as	he publication date of another citation or other specified) g to an oral disclosure, use, exhibition or other	considered to i	avolve an inventive ste one or more other suc	claimed invention cannot be p when the document is h documents, such combination	
"P" document published the priority date of	ed prior to the international filing date but later than aimed		to a person skilled in t ober of the same paters		
	completion of the international search	Date of mailing of			
3 November 1	997		0 4	-11- 1997	
Name and mailing	address of the ISA/	Authorized officer			
	42 STOCKHOLM	Eva Johansso			
Facsimile No. +4	6 8 666 02 86	Telephone No. +46 8 782 25 00			

Inter ... uonal application No.
PCT/DK 97/00166

PCI/DK 37	
ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 9507694 A1 (SANKYO COMPANY, LIMITED ET AL), 23 March 1995 (23.03.95), see particularly page 7	1-7,9-15, 18-22
	8,16,23-32
	*
WO 9640113 A2 (SUGEN, INC.), 19 December 1996 (19.12.96)	1-7,13-15, 18-22
	8-12,23-32
	
WO 9112003 A1 (THE UP-JOHN COMPANY), 22 August 1991 (22.08.91)	1-7,13-15, 18-22
	8-12,16, 23-32
	·
	1-7,13-15, 18-22
	8-12,16, 23-32
EP 0500337 A1 (UNIVERSITY OF COLORADO FOUNDATION, INC.), 26 August 1992 (26.08.92)	1-7,13-15, 18-22
	8-12,16, 23-32
EP 0193256 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 3 Sept 1986 (03.09.86)	1-7,13-15, 18-22
*	8-12,16, 23-32
١	,
	WO 9507694 A1 (SANKYO COMPANY, LIMITED ET AL), 23 March 1995 (23.03.95), see particularly page 7 WO 9640113 A2 (SUGEN, INC.), 19 December 1996 (19.12.96) WO 9112003 A1 (THE UP-JOHN COMPANY), 22 August 1991 (22.08.91) EP 0764632 A2 (ELI LILLY AND COMPANY), 26 March 1997 (26.03.97), see particularly example 9 EP 0500337 A1 (UNIVERSITY OF COLORADO FOUNDATION, INC.), 26 August 1992 (26.08.92) EP 0193256 A1 (TAKEDA CHEMICAL INDUSTRIES, LTD.), 3 Sept 1986 (03.09.86)

International application No.
PCT/DK 97/00166

		PC1/DK 9//UU	100
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the releva	int passages	Relevant to claim No.
x	EP 0339549 A2 (F. HOFFMANN-LA ROCHE AG), 2 November 1989 (02.11.89)		1-7
A			8-16,18-32
X	STN International, File CAPLUS, Accession no. 1996:543848, Yanagisawa, Hiroaki et al: "Preparation of (azolylphenoxy)alkyl aryl heterocyclyl sulfone derivatives having al reductase-inhibitory activity as hypolipid hypoglycemics, and antiobesity agents",	dose	1-7,13-15, 18-22
	Jpn. Kokai Tokkyo Koho, 30 pp., Chemical Abstracts no. 125:195654		0_12 16
A			8-12,16, 23-32
		į	
			•
		-	
	SA/210 (continuation of second sheet) (July 1992)		

International application No.

PCT/DK97/00166

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
This inte	rnational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X	Claims Nos.: 17 because they relate to subject matter not required to be searched by this Authority, namely:	
	See PCT Rule 39.1.(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.	
2. X	Claims Nos.: 1-7, 13-22 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:	
	See extra sheet (*)	
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
This Inte	mational Searching Authority found multiple inventions in this international application, as follows:	
	See extra sheet (##)	
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.	
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:	
4. X	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-32 and the first effect.	
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

Box I

*Claims 1-7 and 13-22 have been searched incompletely. These claims are so broadly formulated that they include thousands of known compounds. These compounds differ structurally essentially from each other and the only uniting feature is the general definition of the effect (or rather the effects).

The effects in claim 15 differ essentially from each other.

Thus, the search has been limited to the combination of the too general definition of the compounds and the first mentioned effect in claim 15.

Box II

- **As the uniting feature is considered to be the effect the following inventions comprising the corresponding compound, method of preparing, pharmaceutical composition, method of modulating, use for preparing medicament, method for purification and use in diagnosis can be seen:
- 1) diabetes, impaired glucose tolerance, insulin resistance, claims 1-32
- 2) obesity, claims 1-32
- 3) immune dysfunction..., claims 1-32
- 4) allergic diseases, claims 1-32
- 5) osteoporosis, claims 1-32
- 6) proliferative disorder..., claims 1-32
- 7)....synthesis or effect of growth hormone, claims 1-32
- 8)....synthesis of hormone or cytokines..., claims 1-32
- 9) diseases of the brain..., claims 1-32
- 10) infectious diseases, claims 1-32

Information on patent family members

International application No. 01/10/97 PCT/DK 97/00166

	tent document in search report	.	Publication date		Patent family member(s)		Publication date
WO	9507694	A1	23/03/95	AU	678291 E	3	22/05/97
			• • • • • •	AU	679 572 E	3	03/07/97
				AU	1770997		29/05/97
				AU	1771097	À	29/05/97
				AU	7724994		03/04/95
				AU	7835194		03/04/95
			•	CA	2168751		23/03/95
				CN	1131391		18/09/96
				CN	1134669		30/10/96
				CZ	9600722		16/10/96
				CZ	9600793		16/10/96
							03/07/96
				EP	0719140		
				EP	0719143		03/07/96
				FI	961213		14/05/96
				HU	75873		28/05/97
				HU	75874		28/05/97
				HU	9600653		00/00/00
				HU	9600674		00/00/00
				JP	9502722		18/03/97
				JP	9502727		18/03/97
				NO	961041		14/05/96
				NO	961052	Α .	14/03/96
				NZ	274346	A	24/06/97
				US	5457109	A	10/10/95
				US	5478852	A	26/12/95
				US	5602133		11/02/97
				WO	9 507697		23/03/95
WO	9640113	A2	19/12/96	AU	6110496	A	30/12/96
WO	9112003	A1	22/08/91	AU	651571	В	28/07/94
				AU	7241691	A	03/09/91
				CA	2071629	Α	10/08/91
			. *	DE	69100282	T	05/01/94
				EP	0514452	A.B	25/11/92
				SE	0514452		
				ES	2059121		01/11/94
				HK	153996		16/08/96
				ÜS	5356913		18/10/94
EP	0764632	A2	26/03/97	AU	7077096	A	09/04/97
C.	V, UTVUL		20, 30, 3,	MO			27/03/97
EP	0500337	A1	26/08/92	AU	650714	B	30/06/94
	100001		20, 30, 32	AU	651865		04/08/94
				UA	1111492		27/08/92
				CA	2061363		23/08/92
				HU	66536		28/12/94
					6048943		22/02/94
				JP			27/10/92
		•		US	5158966		14/08/93
				ZA	9201108	^	14/ 00/ 33

Information on patent family members

01/10/97

International application No.
PCT/DK 97/00166

Patent document cited in search report		Publication date		Patent family member(s)		Publication date	
EP	0193256	A1	03/09/86	SE	0193256	T3	
	•=====			CA	1277323	Α	04/12/90
				DK	21986	Α	20/07/86
				DK	171614	В	24/02/97
				HK	3692	Α	17/01/92
				IE	58928	В	01/12/93
				JP	1853588		07/07/94
				JP	61267580		27/11/86
				MX	9202933	A	30/06/92
EP	0339549	A2	02/11/89	AU	623131	В	07/05/92
LF	0000070	72	02/11/03	AU	3335989	_	26/10/89
				DK	197989		26/10/89
				JP	1313499	A	18/12/89
				US	5182263		26/01/93
-				· US	5296608		22/03/94
			•	ÜS	5508437	Α	16/04/96